Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine | Zendy

Sara Tomczyk | Zendy; Ruth Lynfield | Zendy; William Schaffner | Zendy; Arthur Reingold | Zendy; Lisa A. Miller | Zendy; Susan Petit | Zendy; Corinne Holtzman | Zendy; Shelley M. Zansky | Zendy; Ann Thomas | Zendy; Jan Baumbach | Zendy; Lee H. Harrison | Zendy; Monica M. Farley | Zendy; Bernard Beall | Zendy; Lesley McGee | Zendy; Ryan Gierke | Zendy; Tracy Pondo | Zendy; Lindsay Kim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine

Author(s) -

Sara Tomczyk,

Ruth Lynfield,

William Schaffner,

Arthur Reingold,

Lisa A. Miller,

Susan Petit,

Corinne Holtzman,

Shelley M. Zansky,

Ann Thomas,

Jan Baumbach,

Lee H. Harrison,

Monica M. Farley,

Bernard Beall,

Lesley McGee,

Ryan Gierke,

Tracy Pondo,

Lindsay Kim

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw067

Subject(s) - pneumococcal conjugate vaccine , medicine , antibiotics , serotype , streptococcus pneumoniae , pneumococcal disease , microbiology and biotechnology , antibiotic resistance , virology , biology

Antibiotic-nonsusceptible invasive pneumococcal disease (IPD) decreased substantially after the US introduction of the pediatric 7-valent pneumococcal conjugate vaccine (PCV7) in 2000. However, rates of antibiotic-nonsusceptible non-PCV7-type IPD increased during 2004-2009. In 2010, the 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7. We assessed the impact of PCV13 on antibiotic-nonsusceptible IPD rates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research